Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-17T13:17:24.701Z Has data issue: false hasContentIssue false

The Effect of Topiramate in the Treatment of Opioid (Heroin) Withdrawal

Published online by Cambridge University Press:  16 April 2020

N. Mokhber
Affiliation:
Mashad University of Medical Sciences, Mashad, Iran
A. Soltanifar
Affiliation:
Mashad University of Medical Sciences, Mashad, Iran
M. Talebi
Affiliation:
Mashad University of Medical Sciences, Mashad, Iran

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

This study was carried out on 149 of Heroin dependent patient that admission for detoxification.

Design:

This study is a 10 days double blind placebo-controlled trial.

Place & duration of study:

This study is a 10 days double blind placebo-controlled trial which was carried out on 149 of Heroin dependent patient that admission for detoxification in Mashhad Ebne-sina hospital in 1385-1386 Subjects were randomly divided into topiramate and placebo detoxification groups.

Subjects & methods:

Topiramate group receive topiramate (max 200 mg) for 10 days. The placebo group received usual regimen and placebo. Withdrawal symptoms were assessed by Subjective and Objective Opiate Withdrawal Scale in days 1, 3, 5, 7, 10.information s analyzed by chi-square test for qualities variables and T-test & Mann-Whitney for quantities variables in SPSS software.

Results:

22 subjects were excluded from the study. Both groups had no significant differences in age, sex, education, number of previous withdrawal and past history of other drug use. Result indicates decrease in objective withdrawal symptom significant in 3(p=0.000), 5 (p=0.004) and 7(p=0.026) day and subjective withdrawal symptom significant in 3 (p=0.000) day in topiramate groups.

Conclusion:

Topiramate can use for control of withdrawal symptom in patient with Heroin dependency.

Type
P01-55
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.